0 Items
Toll Free (US) - +1-866-598-1553
sales@precisionbusinessinsights.com
Psoriasis Biologicals Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018-2022 and Forecast 2023-2029

Psoriasis Biologicals Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018-2022 and Forecast 2023-2029

$ PRICE - $ 3,000.00 – $ 8,900.00

Psoriasis Biologicals Market by Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, and Tropical Therapies), Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, and Other Mechanisms of Action), Route of Administration (Oral, Parenteral, and Topical) and Geography

 

Request Sample Request Methodology
Request Sample Read More
$ PRICE - $ 3,000.00 – $ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00 – $ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:
Report

Description

Psoriasis Biologicals market size was valued at USD 24,874.9 million in 2022 and is expected to grow at a CAGR of 9.8% from 2023-2029. Psoriasis is a skin condition that is an autoimmune inflammatory disorder caused by an overproduction of tissue cells on the skin. Over time, the patient will experience symptoms such as excessive dryness, itching, bleeding, and local irritation. In severe cases, the patient feels pricking pain and inflammation on the skin. Psoriatic arthritis and plaque psoriasis are the two types of the disease. Psoriatic arthritis treatments patients typically present with skin conditions as well as joint complaints and pain. Plaque psoriasis, on the other hand, is usually seen in patients with noticeable skin disorders. Many people in the older population have also increased the incidence of psoriasis cases. The widespread usage of biosimilar products has significantly boosted the market. The lucrative offers and programs provided by insurance companies in the form of reimbursement facilities have significantly increased the size of the market over the predicted period. Rapid prescriptions issued by clinics and hospitals to treat these skin disorders drove sales of biologic products into the market, facilitating industry expansion to a large extent. The exorbitant cost of current medications and procedures has severely impeded market expansion. The shortage of disposable income among the population impacted drug sales and demand. The long-term therapy associated with chronic skin conditions costs a lot of money over time, which makes market expansion difficult. The pandemic’s breakout had a huge influence on the psoriasis treatment business. On the one hand, follow-ups and routine hospital visits were impeded due to limited transit and movement due to the lockdowns. On the other hand, due to the growing popularity of online shopping among customers, online retail shops saw increased demand and supply. The patients responded better to this system than to the previous ones. Improved self-care resulted in better outcomes during the epidemic.

Key Developments:

November 2021 – The European Commission has approved AbbVie Inc.’s SKYRIZI subcutaneous injectable for the treatment of active psoriatic arthritis.

Psoriasis Biologicals Market

MARKET SUMMARY
-
9.8%
  • Study Period– 2023 – 2029
  • Base Year– 2022
  • CAGR–  9.8%
  • Largest Market– Asia Pacific
  • Fastest Growing Market–  North America

Psoriasis Biologicals Market

  • The Psoriasis Biologicals Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The Psoriasis Biologicals Market is segmented based on Type of Treatment, Mechanism of Action, Route of Administration, and geography.
Key Players
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZenca
  • Biogen Idec
  • Boehringer Ingelheim
Psoriasis Biologicals Market Dynamics

The rising incidence of psoriasis throughout the world has created a significant need for safe and effective treatment options. For example, according to U.S. Census data, the reported number of cases in the United States in 2020 was roughly 7.55 million. In addition, a MedPage Today, LLC. article published in November 2021 said that a six-month delay in diagnosing psoriatic arthritis might result in joint erosions, damage, and incapacity. Furthermore, a recent wave of biologicals in the treatment of psoriatic diseases is predicted to more than quadruple market size by the end of 2029, leveraging a large market potential for investment in innovative product development and clinical trials.

North-America Got Significant Share

Psoriasis Biologicals Market

The Psoriasis Biologicals market is segmented into America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The Psoriasis Biologicals market in North America is likely to hold a significant revenue share in 2022, and, in the following years, it is predicted to increase rapidly due to the presence of major key players in the region as well as an increase in the prevalence of psoriasis patient in countries such as U.S. Furthermore, high disposable income among the people in North America has driven the development in the healthcare industry due to affordability to invest in highly advanced medication that meets the targeted medical need of the people which further propel the market growth in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Psoriasis Biologicals Market Segmentation

segmentation-block-image

Type

    • Biologic Drugs
    • Small Molecule Systemic Drugs
    • Tropical Therapies
segmentation-block-image

Mechanism of Action

    • TNF Alpha Inhibitors
    • PDE4 Inhibitors
    • Interleukin Inhibitors
    • Other Mechanisms of Action
segmentation-block-image

Route Administration

    • Oral
    • Parenteral
    • Topical
segmentation-block-image

Geography

    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • MEA
Location

GEOGRAPHY

Frequently Asked Questions

North America is growing at the highest CAGR over 2018 – 2028

 

 

 

 

The rise in the prevalence of the disease around the globe, growing strategic collaborations and mergers among key players, and the demand for safe and effective therapies for treatment are some of the factors expected to drive the market during the forecast period..

AbbVie Inc, Amgen Inc, AstraZenca, Biogen Idec, Boehringer Ingelheim, Celgene Corporation, Dr.Reddy`s Laboratories, Eli Lilly and Company, Forward Pharma, Johnson and Johnson (Janssen Biotech Inc.), Leo Pharma AS are the key players of the market.

Report

Table Of Content

1. Executive Summary
2. Global Psoriasis Biologicals Market Introduction
2.1. Global Psoriasis Biologicals Market – Taxonomy
2.2. Global Psoriasis Biologicals Market –Definitions
2.2.1. By Type of Treatment
2.2.2. By Mechanism of Action
2.2.3. By Route of Administration
2.2.4. By Region
3. Global Psoriasis Biologicals Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Psoriasis Biologicals Market Dynamic Factors – Impact Analysis
3.6. Global Psoriasis Biologicals Market – Competition Landscape
4. Global Psoriasis Biologicals Market Analysis,2018 – 2022 and Forecast, 2023 – 2029
4.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Psoriasis Biologicals Market, By Type of Treatment, 2018–2022and Forecast, 2023–2029 (Revenue, USD Mn)
5.1. Biologic Drugs
5.1.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Small Molecule Systemic Drugs
5.2.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Tropical Therapies
5.3.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Psoriasis Biologicals Market, By Mechanism of Action, 2018 – 2022 and Forecast, 2022 – 2027 (Revenue, USD Mn)
6.1. TNF Alpha Inhibitors
6.1.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. PDE4 Inhibitors
6.2.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Interleukin Inhibitors
6.3.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Other Mechanisms of Action
6.4.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Psoriasis Biologicals Market, By Route of Administration, 2018 – 2022 and Forecast, 2022 – 2027 (Revenue, USD Mn)
7.1. Oral
7.1.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Parenteral
7.2.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Topical
7.3.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Psoriasis Biologicals Market Forecast, By Region, 2018–2022and Forecast, 2023–2029(Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Psoriasis Biologicals Market – Opportunity Analysis Index, By Type of Treatment, Mechanism of Action, Route of Administration, and Region, 2023 – 2029
9. North America Psoriasis Biologicals market analysis,2018–2022and Forecast, 2023–2029(Revenue, USD Mn)
9.1. Type of Treatment Analysis 2018–2022and Forecast 2023 – 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Biologic Drugs
9.1.2. Small Molecule Systemic Drugs
9.1.3. Tropical Therapies
9.2. Mechanism of Action Analysis 2018–2022and Forecast 2023 – 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. TNF Alpha Inhibitors
9.2.2. PDE4 Inhibitors
9.2.3. Interleukin Inhibitors
9.2.4. Other Mechanisms of Action
9.3. Route of Administration Analysis 2018 – 2022 and Forecast 2023 – 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Oral
9.3.2. Parenteral
9.3.3. Topical
9.4. Country Analysis 2018 – 2022 and Forecast 2023 – 2029by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Psoriasis Biologicals Market – Opportunity Analysis Index, By Type of Treatment, Mechanism of Action, Route of Administration, and Country, 2023 – 2029
9.6. North America Psoriasis Biologicals Market Dynamics – Trends
10. Europe Psoriasis Biologicals Market Analysis, 2018–2022and Forecast, 2023–2029(Revenue, USD Mn)
10.1. Type of Treatment Analysis 2018–2022and Forecast 2023 – 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Biologic Drugs
10.1.2. Small Molecule Systemic Drugs
10.1.3. Tropical Therapies
10.2. Mechanism of Action Analysis 2018–2022and Forecast 2023 – 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. TNF Alpha Inhibitors
10.2.2. PDE4 Inhibitors
10.2.3. Interleukin Inhibitors
10.2.4. Other Mechanisms of Action
10.3. Route of Administration Analysis 2018 – 2022 and Forecast 2023 – 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Topical
10.4. Country Analysis 2018–2022and Forecast 2023 – 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Psoriasis Biologicals Market – Opportunity Analysis Index, By Type of Treatment, Mechanism of Action, Route of Administration, and Country, 2023 – 2029
10.6. Europe Psoriasis Biologicals Market Dynamics – Trends
11. Asia-Pacific Psoriasis Biologicals Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
11.1. Type of Treatment Analysis 2018–2022and Forecast 2023 – 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Biologic Drugs
11.1.2. Small Molecule Systemic Drugs
11.1.3. Tropical Therapies
11.2. Mechanism of Action Analysis 2018–2022and Forecast 2023 – 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. TNF Alpha Inhibitors
11.2.2. PDE4 Inhibitors
11.2.3. Interleukin Inhibitors
11.2.4. Other Mechanisms of Action
11.3. Route of Administration Analysis 2018 – 2022 and Forecast 2023 – 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Topical
11.4. Country Analysis2018–2022and Forecast 2023 – 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Psoriasis Biologicals Market – Opportunity Analysis Index, By Type of Treatment, Mechanism of Action, Route of Administration, and Country,2023 – 2029
11.6. Asia-Pacific Psoriasis Biologicals Market Dynamics – Trends
12. Latin America Psoriasis Biologicals Market Analysis,2018 – 2022 and Forecast, 2023–2029(Revenue, USD Mn)
12.1. Type of Treatment Analysis 2018–2022and Forecast 2023 – 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Biologic Drugs
12.1.2. Small Molecule Systemic Drugs
12.1.3. Tropical Therapies
12.2. Mechanism of Action Analysis 2018–2022and Forecast 2023 – 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. TNF Alpha Inhibitors
12.2.2. PDE4 Inhibitors
12.2.3. Interleukin Inhibitors
12.2.4. Other Mechanisms of Action
12.3. Route of Administration Analysis 2018 – 2022 and Forecast 2023 – 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Topical
12.4. Country Analysis 2018–2022and Forecast 2023 – 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Psoriasis Biologicals Market – Opportunity Analysis Index, By Type of Treatment, Mechanism of Action, Route of Administration, and Country, 2023 – 2029
12.6. Latin America Psoriasis Biologicals Market Dynamics – Trends
13. Middle East and Africa Psoriasis Biologicals Market Analysis, 2018 – 2022 and Forecast, 2023 – 2029 (Revenue, USD Mn)
13.1. Type of Treatment Analysis 2018–2022and Forecast 2023 – 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Biologic Drugs
13.1.2. Small Molecule Systemic Drugs
13.1.3. Tropical Therapies
13.2. Mechanism of Action Analysis 2018–2022and Forecast 2023 – 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. TNF Alpha Inhibitors
13.2.2. PDE4 Inhibitors
13.2.3. Interleukin Inhibitors
13.2.4. Other Mechanisms of Action
13.3. Route of Administration Analysis 2018 – 2022 and Forecast 2023 – 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Topical
13.4. Country Analysis 2018 – 2022 and Forecast 2023 – 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Psoriasis Biologicals Market – Opportunity Analysis Index, By Type of Treatment, Mechanism of Action, Route of Administration, and Country, 2023 – 2029
13.6. MEA Psoriasis Biologicals Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Type of Treatment& Service Testing Type of Treatments, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AbbVie Inc.
14.2.2. Amgen Inc.
14.2.3. AstraZenca
14.2.4. Biogen Idec
14.2.5. Boehringer Ingelheim
14.2.6. Celgene Corporation
14.2.7. Dr.Reddy`s Laboratories
14.2.8. Eli Lilly and Company
14.2.9. Forward Pharma
14.2.10. Johnson and Johnson (Janssen Biotech Inc.)
14.2.11. Leo Pharma AS
15. Research Methodology
16. Key Assumptions and Acronyms
Report

Company Profile

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZenca
  • Biogen Idec
  • Boehringer Ingelheim
  • Celgene Corporation
  • Reddy`s Laboratories
  • Eli Lilly and Company
  • Forward Pharma
  • Johnson and Johnson (Janssen Biotech Inc.)
  • Leo Pharma AS.

Description

Psoriasis Biologicals market size was valued at USD 24,874.9 million in 2022 and is expected to grow at a CAGR of 9.8% from 2023-2029. Psoriasis is a skin condition that is an autoimmune inflammatory disorder caused by an overproduction of tissue cells on the skin. Over time, the patient will experience symptoms such as excessive dryness, itching, bleeding, and local irritation. In severe cases, the patient feels pricking pain and inflammation on the skin. Psoriatic arthritis and plaque psoriasis are the two types of the disease. Psoriatic arthritis treatments patients typically present with skin conditions as well as joint complaints and pain. Plaque psoriasis, on the other hand, is usually seen in patients with noticeable skin disorders. Many people in the older population have also increased the incidence of psoriasis cases. The widespread usage of biosimilar products has significantly boosted the market. The lucrative offers and programs provided by insurance companies in the form of reimbursement facilities have significantly increased the size of the market over the predicted period. Rapid prescriptions issued by clinics and hospitals to treat these skin disorders drove sales of biologic products into the market, facilitating industry expansion to a large extent. The exorbitant cost of current medications and procedures has severely impeded market expansion. The shortage of disposable income among the population impacted drug sales and demand. The long-term therapy associated with chronic skin conditions costs a lot of money over time, which makes market expansion difficult. The pandemic’s breakout had a huge influence on the psoriasis treatment business. On the one hand, follow-ups and routine hospital visits were impeded due to limited transit and movement due to the lockdowns. On the other hand, due to the growing popularity of online shopping among customers, online retail shops saw increased demand and supply. The patients responded better to this system than to the previous ones. Improved self-care resulted in better outcomes during the epidemic.

Key Developments:

November 2021 – The European Commission has approved AbbVie Inc.’s SKYRIZI subcutaneous injectable for the treatment of active psoriatic arthritis.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX

QUICKLINKS
RESEARCH AREAS
PRESS RELEASE
CONTACT US
+1-866-598-1553
EMAIL
sales@precisionbusinessinsights.com
FOLLOW US
QUICK LINKS+
RESEARCH AREAS+
PRESS RELEASE+
CONTACT US+
+1-866-598-1553
sales@precisionbusinessinsights.com
FOLLOW US AT+